UBS Is Bullish on China Biotech, CRO, and AI Drug Discovery as Licensing Deals, Profits Grow(Yicai) Nov. 18 -- Against the backdrop of improving profitability and continued growth in out-licensing deals among Chinese innovative drugmakers, UBS Securities is most optimistic about local biotech, contract research organizations, and artificial intelligence-driven drug discovery, according to the head of China healthcare research at the securities firm.
The market logic for investing in the Chinese biotech sector is shifting, Chen Chen told Yicai recently. In the past, investors focused more on research and development pipelines and individual clinical data, but the framework is maturing and now focuses on whether innovation can ultimately translate into revenue, profit, and cash flow, she pointed out.
Most companies covered by UBS are expected to break even around next year, she said. 91 Chinese mainland and Hong Kong-listed biopharmaceutical firms reported a combined net profit of about CNY5.5 billion (USD825 million) in the first half of this year, versus a combined loss of about CNY7.4 billion a year earlier.
The acceleration of out-licensing agreements is also an important support factor, with the value and upfront payments of such deals signed by Chinese drugmakers this year already exceeding last year's total.
One of 2026's highlights is the continued emergence of new licensing and collaboration deals, which are gradually evolving from one-way licensing into portfolio-based and platform-based partnerships, Chen said. Global pharma companies are increasingly recognizing the innovative capabilities of Chinese drugmakers, she added.
Looking ahead to next year, the most important catalysts for the innovative drug sector will be the release of key clinical data, progress in approvals for new products and indications, and the size of price cuts for major products after this year's national medical insurance negotiation, she pointed out.
In addition, supported by a rebound in global R&D demand and rising experimental validation needs in emerging AIDD, CRO, and contract development and manufacturing organizations, companies have seen a notable increase in new orders and backlogs, she noted. R&D demand in China is also gradually recovering, with the preclinical rebound more pronounced than the clinical-stage one, she added.
As for AIDD, no drugs in the world have been fully designed by AI, successfully passed Phase III clinical trials, and been released on the market. The industry is still in an observational and validation stage, which at least points to a scientifically promising breakthrough direction, with AI able to improve drug development efficiency in some phases, Chen said.
Editor: Martin Kadiev
